With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.189333-49-1,3-Benzyl-3,9-diazaspiro[5.5]undecane,as a common compound, the synthetic route is as follows.
Step C Preparation of (S)-tert.-butyl 2-benzenesulfonylamino-5-oxo-5-(9-phenylmethyl-3,9-diazaspiro[5.5]undecan-3-yl)pentanoate A solution of 6.82 g (19.86 mmol) of the intermediate from Step B in 20 ml dry THF containing 2.8 ml triethylamine was cooled to -10 C. 2.15 g (19.8 mmol) ethyl chloroformate were added dropwise, and the mixture was stirred for ten minutes, while a precipitate was formed spontaneously. A solution of 4.85 g (19.86 mmol) of the intermediate from Example 20, Step D in a mixture of 24 ml dry THF and 5.3 ml triethylamine was added quickly in small portions. It was warmed to room temperature, stirred over night, poured into water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, and concentrated under reduced pressure, and the title compound was obtained by chromatography on silica gel with dichloromethane/ethanol 93:7. yield: 3.9 g (34%) colorless crystalline solid, m.p. 134-136 C., 189333-49-1
The synthetic route of 189333-49-1 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; Eli Lilly and Company; COR Therapeutics Inc.; US6291469; (2001); B1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem